Tenet Healthcare
THC
$264.51
+0.31%
Tenet Healthcare Corporation is a Dallas-based healthcare services organization that operates 50 acute and specialty hospitals and hundreds of ambulatory surgery centers and outpatient facilities across the United States, primarily concentrated in the South, alongside its Conifer segment that provides revenue cycle management solutions. As one of the largest investor-owned hospital operators in the country, Tenet has evolved from a highly leveraged turnaround story into a diversified care delivery platform, with its Ambulatory Care segment now representing a meaningful and fast-growing profit engine alongside traditional Hospital Operations. The current investor narrative centers on Tenet's aggressive deleveraging and capital return program, evidenced by $318 million in stock repurchases in Q1 2026 alone, combined with a strong Q1 2026 earnings beat that prompted management to raise full-year profit guidance despite a revenue shortfall attributed to unfavorable patient insurance mix. The stock has responded dramatically, surging over 50% in the past three months as the market increasingly views Tenet as a cash-generative, margin-expanding operator rather than a balance-sheet-constrained hospital chain, though questions persist about the sustainability of margin gains and the impact of payer mix headwinds on future revenue growth.…
THC
Tenet Healthcare
$264.51
Related headlines
Investment Opinion: Should I buy THC Today?
Tenet Healthcare earns a Buy rating, supported by a strong buy analyst consensus (recommendation mean 1.5) and an average target price of $285.10, implying 8.1% upside. The core thesis is that Tenet is a cash-generative, deleveraging hospital operator trading at a deep discount to peers on cash flow metrics, with a growing ambulatory segment that should drive margin expansion. While the upside to the average target is modest, the high target of $315.00 suggests 19.5% potential if management executes on buybacks and debt reduction.
The supporting evidence is compelling: Tenet trades at 6.29x EV/EBITDA versus the healthcare sector's 10-12x average, and 0.84x PS, both well below historical norms. Revenue grew 2.78% year-over-year in Q1 2026, but profitability is robust with a 13.08% net margin and 29.17% EBITDA margin. Free cash flow of $3.349 billion TTM funds $318 million in quarterly buybacks and debt reduction, while ROE of 33.34% demonstrates efficient capital deployment. The ambulatory segment, at $1.32 billion in quarterly revenue, is a high-growth, high-margin engine that should lift consolidated margins over time.
The biggest risks are revenue deceleration, high leverage (debt-to-equity of 3.12), and the potential for margin compression from unfavorable payer mix. The rating would upgrade to a stronger Buy if revenue growth accelerates above 5% or if EV/EBITDA remains below 7x with continued debt reduction. It would downgrade to Hold if revenue growth turns negative or if net margin falls below 10%. Relative to its own history and peers, Tenet appears undervalued on cash flow metrics but fairly valued on earnings, suggesting a balanced risk/reward with a slight edge to the bulls.
Sign up to view all
THC 12-Month Price Forecast
Tenet presents a compelling value opportunity with strong cash flow generation and a clear capital return story, but the modest 8.1% upside to the average analyst target and decelerating revenue growth temper enthusiasm. The stock's 50.97% three-month rally has already captured much of the near-term optimism, and the low target of $260 suggests limited margin of safety. The key driver will be whether management can sustain the Q1 2026 margin gains (13.08% net margin) amid payer mix headwinds. I would upgrade to high confidence if revenue growth accelerates above 4% or if the stock pulls back to the $240-250 range, improving the risk/reward. A downgrade would occur if net margin falls below 10% or if debt reduction stalls.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $285.10 and implied upside of +7.8% versus the current price.
Average Target
$285.10
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$260 - $315
Analyst target range
Tenet Healthcare is covered by 21 analysts, reflecting robust institutional interest for a mid-cap healthcare operator. The consensus recommendation is a strong buy, with a recommendation mean of 1.5 on a scale where 1 equals strong buy and 5 equals strong sell, indicating that the analyst community is overwhelmingly bullish on the stock. The average target price is $285.10, which implies approximately 8.1% upside from the current price of $263.69, a relatively modest expected return that suggests analysts believe the stock is approaching fair value after its recent rally. The consensus leans bullish, but the limited upside to the average target indicates that much of the positive fundamental story may already be priced in, and the stock's recent 50.97% three-month gain has likely captured a significant portion of the analysts' price targets. The target price range spans from a low of $260.00 to a high of $315.00, a spread of $55.00 or approximately 21% of the current price, which signals moderate uncertainty but also meaningful divergence in analyst views. The high target of $315.00 implies roughly 19.5% upside and likely assumes continued margin expansion, successful ambulatory segment growth, further debt reduction, and multiple expansion as the market recognizes Tenet's improved cash flow profile. The low target of $260.00, which is actually 1.4% below the current price, suggests a more conservative view that may price in margin compression from unfavorable payer mix, potential regulatory headwinds, or a broader market correction that compresses healthcare valuations. Institutional ratings data shows a consistent pattern of bullish calls, with Wells Fargo, Barclays, TD Cowen, Stephens & Co., KeyBanc, RBC Capital, and Guggenheim all maintaining Overweight, Buy, or Outperform ratings as of mid-2026, while Baird remains the lone Neutral voice. The absence of any Sell ratings and the predominance of Buy-equivalent ratings suggest strong conviction in the Tenet story, though the fact that the average target implies only single-digit upside suggests analysts may be waiting for the next catalyst, such as Q2 2026 earnings or an acceleration in ambulatory segment growth, before raising targets further.
Bulls vs Bears: THC Investment Factors
The bull case currently has stronger evidence, driven by Tenet's deep cash-flow valuation (6.29x EV/EBITDA), aggressive buybacks, and unanimous strong buy analyst consensus. However, the bear case is not without merit: revenue growth has decelerated to 2.78%, leverage remains high at 3.12x debt-to-equity, and the stock's 50.97% three-month rally has left only 8.1% upside to the average analyst target. The single most important tension is whether Tenet can sustain its recent margin expansion (13.08% net margin in Q1 2026) in the face of unfavorable payer mix and rising interest costs. If margins hold, the stock can re-rate toward the high target of $315; if they compress, the low target of $260 or the 52-week low of $157.58 becomes the relevant reference point.
Bullish
- Strong Buy Consensus, 8% Upside: All 21 covering analysts rate Tenet a strong buy (recommendation mean 1.5), with an average target price of $285.10 implying 8.1% upside from the current $263.69. The high target of $315.00 suggests 19.5% upside if margin expansion and deleveraging continue, and there are zero sell ratings.
- Deep Value on Cash Flow Metrics: Tenet trades at just 6.29x EV/EBITDA and 0.84x PS, well below the healthcare sector's typical 10-12x EV/EBITDA range. With $3.349 billion in trailing twelve-month free cash flow and a 29.17% EBITDA margin, the market is paying a steep discount for each dollar of cash generation.
- Aggressive Deleveraging and Buybacks: Management repurchased $318 million of stock in Q1 2026 alone and $747 million in Q2 2025, while generating $1.461 billion in quarterly free cash flow. This capital return program, funded entirely from operations, is shrinking the share count and accelerating EPS growth without adding leverage.
- Ambulatory Segment as Growth Engine: The Ambulatory Care segment generated $1.32 billion in Q1 2026 revenue, roughly 24.6% of the total, and likely carries higher margins and faster growth than the legacy hospital business. As this mix shifts, consolidated margins should structurally improve beyond the current 16.14% operating margin.
Bearish
- Revenue Growth Decelerating to 2.78%: Q1 2026 revenue grew just 2.78% year-over-year to $5.368 billion, a sharp deceleration from prior periods. The revenue miss was attributed to unfavorable patient insurance mix, a headwind that could persist and limit operating leverage even as costs are controlled.
- High Leverage Constrains Flexibility: Tenet carries a debt-to-equity ratio of 3.12 and a total debt-to-capitalization ratio of 73.29%, leaving it vulnerable to rising interest rates. Interest expense was $205 million in Q1 2026, consuming roughly 13% of revenue and limiting the pace of further deleveraging.
- Quality of Earnings Concerns: Q1 2026 net income of $702 million included a $250 million gain in total other income and benefited from a low 19.96% effective tax rate. Excluding these items, core earnings power is lower, and the 13.08% net margin may not be sustainable if one-time gains do not recur.
- Limited Analyst Upside After Rally: The average analyst target of $285.10 offers only 8.1% upside, and the low target of $260.00 is 1.4% below the current price. After a 50.97% three-month rally, much of the near-term fundamental story appears priced in, leaving little margin of safety.
THC Technical Analysis
Tenet Healthcare is in a powerful sustained uptrend, with the stock up 36.36% over the past year and trading at 263.69, which represents approximately 84.3% of its 52-week range (52-week low of 157.58 and high of 283.05). This positioning near the upper end of the annual range signals strong momentum but also raises the risk of overextension, particularly given that the stock has already recovered 34.08% from its maximum drawdown. The current price sits just 6.8% below the 52-week high of 283.05, suggesting that buyers remain in control and that any breakout above this level could trigger a new leg higher, while the 52-week low of 157.58 now stands as a distant floor that would require a 40% decline to revisit. Recent momentum has been mixed but constructive on balance, with the 3-month change of +50.97% far outpacing the 1-year gain of +36.36%, indicating that the bulk of the rally has occurred in the last quarter. However, the 1-month change of -1.16% reveals a modest pullback and consolidation phase, diverging from the explosive 3-month trajectory and suggesting the stock is digesting its gains rather than reversing trend. This divergence is further supported by the relative strength metrics: the 3-month relative strength versus SPY is an impressive +47.93%, but the 1-month relative strength has slipped to -0.10%, meaning Tenet has slightly underperformed the broader market over the past month after a period of dramatic outperformance. The 6-month relative strength of just +0.44% further underscores that the rally was concentrated in the March-to-June window, and the stock has since moved largely in line with the market. Key technical levels are well-defined: immediate resistance sits at the 52-week high of 283.05, and a decisive breakout above this level on strong volume would confirm the uptrend's continuation and likely attract momentum buyers. On the downside, the 52-week low of 157.58 represents the ultimate support, but intermediate support likely exists around the 250-255 area, which corresponds to the late-July and early-August consolidation zone. With a beta of 1.23, Tenet is approximately 23% more volatile than the broader market, meaning position sizing should account for amplified drawdowns during market corrections; the maximum drawdown of -34.08% over the past year illustrates this risk vividly. The current short ratio of 2.38 suggests short sellers are not aggressively positioned against the stock, which reduces the potential for a short squeeze but also indicates that bearish sentiment is relatively muted.
Beta
1.23
1.23x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$158-$283
Price range past year
Annual Return
+37.2%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | -1.3% | -2.0% |
| 3m | +44.1% | +1.4% |
| 6m | +30.2% | +15.0% |
| 1y | +37.2% | +15.7% |
| ytd | +32.6% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Tenet's revenue trajectory shows steady but modest growth, with Q1 2026 revenue of $5.368 billion representing a 2.78% year-over-year increase from Q1 2025's $5.223 billion. The multi-quarter trend reveals a company that is growing in the low-single digits, with quarterly revenue progressing from $5.103 billion in Q2 2024 to $5.272 billion in Q2 2025 and $5.368 billion in Q1 2026, indicating consistent sequential expansion but at a pace that is decelerating relative to the double-digit growth seen in prior years. Segment data shows Hospital Operations generating $4.048 billion and Ambulatory Care contributing $1.32 billion, with the ambulatory segment representing roughly 24.6% of total revenue but likely commanding a higher growth rate and margin profile, making it the strategic growth engine for the company. The Q1 2026 revenue miss, attributed to unfavorable patient insurance mix, highlights a key risk: while volumes may be stable, the quality of revenue (payer mix) directly impacts profitability, and management's ability to offset this through cost controls and ambulatory expansion will determine whether the growth trajectory can reaccelerate. Profitability metrics are robust, with Q1 2026 net income of $702 million and a net margin of 13.08%, a significant improvement from the 6.71% net margin in Q4 2025 and 7.77% in Q1 2025. The gross margin of 16.43% in Q1 2026 appears low in absolute terms but is consistent with the hospital industry's cost structure, where cost of revenue includes substantial direct patient care expenses; the operating margin of 16.14% and EBITDA of $1.566 billion (29.17% EBITDA margin) demonstrate strong operational efficiency. Notably, the Q1 2026 net income of $702 million benefited from a lower effective tax rate of 19.96% and a $250 million gain in total other income, which may not be recurring, so investors should monitor whether the margin expansion is driven by sustainable operational improvements or one-time items. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 3.12 and a total debt-to-capitalization ratio of 73.29%, which is high but typical for the hospital industry given the capital-intensive nature of the business. However, the company generates substantial free cash flow, with $3.349 billion in trailing twelve-month free cash flow and $1.461 billion in Q1 2026 alone, providing ample liquidity to service debt and fund buybacks. The current ratio of 1.76 and cash position of $2.967 billion at the end of Q1 2026 indicate solid short-term liquidity, while the ROE of 33.34% reflects the company's ability to generate strong returns on its equity base despite the leverage. The interest coverage ratio of 4.30x provides a comfortable cushion for debt servicing, and the company's aggressive share repurchases ($318 million in Q1 2026, $747 million in Q2 2025) signal management's confidence in the company's cash generation and its commitment to returning capital to shareholders.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+2.8%
YoY Comparison
Gross Margin
16.4%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
With net income firmly positive at $702 million in Q1 2026 and $371 million in Q4 2025, the PE ratio is the appropriate primary valuation metric for Tenet. The trailing PE of 12.73x and forward PE of 12.51x are remarkably close, implying that the market is not pricing in significant earnings growth over the next twelve months, which is unusual for a company that has been beating earnings estimates and raising guidance. This tight spread suggests that either the market is skeptical about the sustainability of recent margin gains or that the stock is fairly valued relative to its near-term earnings power, with the forward PE of 12.51x based on estimated EPS of $28.72 providing a modest 1.7% earnings growth assumption. Compared to the broader healthcare sector, where hospital operators and medical care facilities typically trade at PE multiples ranging from 15x to 20x, Tenet's trailing PE of 12.73x represents a discount of approximately 15% to 36% depending on the peer set. The PS ratio of 0.84x is notably low for a company with a 13.08% net margin and 16.14% operating margin, suggesting the market is undervaluing Tenet's revenue stream relative to its profitability. The EV/EBITDA of 6.29x is also attractive, particularly when compared to the healthcare sector's average EV/EBITDA of 10x to 12x, indicating that Tenet's enterprise value is modest relative to its cash-generating capacity. This discount may be justified by the company's high leverage (debt-to-equity of 3.12) and the capital-intensive nature of the hospital business, but it also presents a potential value opportunity if the company continues to deleverage and expand margins. Historically, Tenet's PE ratio has ranged from a low of 1.21x in Q1 2024 (distorted by a one-time gain) to a high of 37.54x in Q2 2022, with more typical levels in the 7x to 14x range over the past three years. The current trailing PE of 12.73x sits near the upper end of this historical range, suggesting that the market is pricing in optimistic expectations relative to the company's own trading history. However, the PS ratio of 0.84x is near the low end of its historical range (which has ranged from 1.02x to 3.38x over the past three years), creating a conflicting signal: while earnings-based valuation appears elevated, revenue-based valuation appears depressed. This divergence likely reflects the market's recognition that Tenet's margins have expanded significantly, making the PE ratio a less favorable comparison point, while the PS ratio understates the company's improved profitability profile.
PE
12.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Tenet's financial risk profile is dominated by its substantial debt load, with a debt-to-equity ratio of 3.12 and total debt-to-capitalization of 73.29%. Interest expense of $205 million per quarter consumes a meaningful share of operating income, and with a beta of 1.23, the company is sensitive to rising rates. While free cash flow of $3.349 billion TTM provides ample coverage (interest coverage of 4.30x), the capital-intensive nature of hospital operations means any revenue shortfall could quickly pressure cash flow and delay deleveraging. Additionally, Q1 2026 net income of $702 million included a $250 million non-recurring other income gain and a low 19.96% tax rate, suggesting core earnings power may be lower than headline figures imply.
Market and competitive risks center on Tenet's premium valuation relative to its own history and the potential for multiple compression. The trailing PE of 12.73x sits near the upper end of its three-year range (7x-14x), while the PS ratio of 0.84x is near the low end, creating conflicting signals. If the market begins to question the sustainability of margin gains, the stock could de-rate toward the low analyst target of $260, which is 1.4% below the current price. Competitive pressures from nonprofit hospital systems and outpatient migration, plus regulatory risks such as potential changes to Medicare/Medicaid reimbursement, could also weigh on results. The recent news highlighting the Q1 revenue miss due to unfavorable patient insurance mix underscores that payer mix is a persistent industry headwind.
In a worst-case scenario, a combination of margin compression from unfavorable payer mix, rising interest rates increasing debt service costs, and a broad market correction could trigger a significant drawdown. The 52-week low of $157.58 represents a 40% decline from the current price of $263.69, and the maximum drawdown over the past year was 34.08%. If Q2 2026 earnings miss and management lowers guidance, the stock could quickly test the $200-220 range, and a break below the 52-week low would imply a loss of roughly 40% from current levels. This scenario would likely coincide with a recession or a sharp increase in uncompensated care.
FAQ
The most severe risk is high leverage: debt-to-equity of 3.12 and total debt-to-capitalization of 73.29%, with $205 million in quarterly interest expense. Second, revenue growth has decelerated to 2.78% year-over-year, and unfavorable payer mix could further pressure margins. Third, the stock is volatile with a beta of 1.23 and a 34.08% maximum drawdown over the past year, meaning a market correction could hit Tenet harder than the broader market. Fourth, regulatory changes to Medicare/Medicaid reimbursement could reduce revenue and profitability. These risks are ranked from most to least severe, with leverage and payer mix being the most immediate concerns.
Our 12-month forecast assigns a 55% probability to the base case, targeting $270-290, which assumes 2-3% revenue growth and stable margins, aligning with the analyst average target of $285.10. The bull case (25% probability) targets $300-315, driven by margin expansion and accelerated buybacks, while the bear case (20% probability) targets $200-260, reflecting margin compression and rising interest costs. The most likely scenario is the base case, with the key assumption that Tenet maintains its net margin above 12% and continues modest buybacks. A break above the 52-week high of $283.05 would increase the odds of the bull case, while a drop below $250 would raise bear-case probabilities.
Tenet appears undervalued on cash flow metrics but fairly valued on earnings. The EV/EBITDA of 6.29x is a 37-48% discount to the healthcare sector's 10-12x average, and the PS ratio of 0.84x is near the low end of its three-year range (1.02x-3.38x). However, the trailing PE of 12.73x is near the upper end of its historical 7x-14x range, suggesting the market is pricing in optimistic earnings expectations. The forward PE of 12.51x implies just 1.7% EPS growth, which seems conservative given the buyback-driven EPS accretion. Overall, the market is paying a fair price for current earnings but a discount for cash flow, implying skepticism about margin sustainability.
Tenet offers a favorable risk/reward for value-oriented investors, with a strong buy analyst consensus (1.5 mean) and an average target of $285.10 implying 8.1% upside. The stock trades at just 6.29x EV/EBITDA and 0.84x PS, well below healthcare sector averages, while generating $3.349 billion in free cash flow. However, the 50.97% three-month rally has left limited near-term upside, and the low target of $260 is slightly below the current price. The biggest downside risk is a 40% decline to the 52-week low of $157.58 if margins compress. It is a good buy for patient investors with a 12-18 month horizon who can tolerate volatility (beta 1.23), but short-term traders may find better entry points on a pullback to $250.
Tenet is better suited for a long-term investment horizon of at least 12-18 months, given its deleveraging and capital return story, which requires time to play out. The stock does not pay a dividend (payout ratio 0%), so returns depend entirely on price appreciation and buybacks. With a beta of 1.23 and a 34.08% max drawdown, short-term trading carries significant volatility risk. Earnings visibility is moderate, with analysts estimating EPS of $28.72 for the next year, but quarterly fluctuations can be sharp. A minimum holding period of one year is recommended to capture the full benefit of debt reduction and ambulatory segment growth, while short-term traders should use tight stop-losses given the potential for 10-15% swings.